adt + nilutamide + flutamide + bicalutamide

This is a combination therapy consisting of androgen deprivation therapy (ADT) plus three first-generation non-steroidal antiandrogens: nilutamide, flutamide, and bicalutamide. ADT refers to treatments that lower androgen levels or block their effects, commonly achieved through luteinizing hormone-releasing hormone (LHRH) analogs/antagonists or surgical castration. Nilutamide, flutamide, and bicalutamide are all oral non-steroidal antiandrogens that act as competitive antagonists at the androgen receptor. They inhibit the action of androgens (such as testosterone and dihydrotestosterone) on prostate cancer cells by blocking their binding to the androgen receptor. This combination would result in maximal blockade of the androgen receptor pathway but is not a standard regimen; typically only one antiandrogen is combined with ADT due to overlapping mechanisms and toxicity profiles[1][2][6]. The primary indication for these agents individually or in standard combinations with ADT is advanced/metastatic prostate cancer.